• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Flexible Sensors Detect Heavy Metals in Sweat

      Flexible Sensors Detect Heavy Metals in Sweat

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

    • Radiology
      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Fluorescence Imaging System Illuminates Tumor Depth

      Fluorescence Imaging System Illuminates Tumor Depth

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

    • Cardiology
      Belt Monitors Heart Failure Patients

      Belt Monitors Heart Failure Patients

      Camera Measures Blood Pressure with Quick Look

      Camera Measures Blood Pressure with Quick Look

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Surgery
      Microneedle Bandage for Hemostatic Control

      Microneedle Bandage for Hemostatic Control

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Nanomedicine
      Extra Hot Nanoparticles for Cancer Therapy

      Extra Hot Nanoparticles for Cancer Therapy

      Making Tumors Tastier for the Immune System

      Making Tumors Tastier for the Immune System

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Magnetic Bacteria Target Tumors

      Magnetic Bacteria Target Tumors

    • Military Medicine
      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fabric Makes Electricity from Movement to Power Wearables

      Fabric Makes Electricity from Movement to Power Wearables

      Wearable Uses Microneedles to Track Metabolism

      Wearable Uses Microneedles to Track Metabolism

    • Rehab
      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Implanted Magnets for Prosthetic Control

      Implanted Magnets for Prosthetic Control

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023

January 11th, 2018 Kuick Research Releases

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink:https://www.kuickresearch.com/report-cd-antigen-cancer-therapy-market-outlook-and-clinical-trials-insight-2023.php

 

Table of Contents

 

1. Introduction to CD Antigen Based Cancer Therapeutics

  1.1 Prologue to CD Antigens

  1.2 Background: Discovering CD Antigens in Cancer Therapy

  1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells

  2.1 CD Antigens in Normal Cells

  2.2 CD Antigens in Cancer

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens

  4.1 Monoclonal Antibodies

  4.2 Antibody Drug Conjugates

  4.3 Bispecific Antibodies

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics

  5.1 CAR-T Cell Therapy

  5.2 Aptamers

  5.3 Immunoconjugates

    5.3.1 Radio Immunoconjugate

    5.3.2 Toxin Immunoconjugate

  5.4 Novel CD Antigen Based Antibodies

    5.4.1 Bispecific T-Cell Engager Antibody  (BiTEs)

    5.4.2 DART and TandAb

6. Major CD Antigens as Targets for Cancer Therapy

  6.1 CD20

  6.2 CD19

  6.3 CD137

  6.4 CD38

  6.5 CD70

  6.6 CD22

  6.7 CD30

  6.8 CD33

  6.9 CD37

7. Major CD Antigens as Cancer Diagnostic Agents

  7.1 CD20

  7.2 CD5

  7.3 CD56

  7.4 CD66e

  7.5 CD15

  7.6 CD30

  7.7 CD3

8. Major CD Antigens in Cancer Research

  8.1 CD34

  8.2 CD10

  8.3 CD26

  8.4 CD117

  8.5 CD44

  8.6 CD57

9. Global CD Antigen Based Therapeutics Market Overview

  9.1 Market Progression

  9.2 Current Market Scenario

  9.3 Global CD Antigen Based Cancer Therapeutics Market Trends

  9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview

10. Price and Dosage Analysis of Major CD Antigen Based Cancer Therapies

  10.1 Rituximab (CD20)

  10.2 Ofatumumab (CD20)

  10.3 Obinutuzumab (CD20)

  10.4 Daratumumab (CD38)

  10.5 Brentuximab Vedotin (CD30)

  10.6 Gemtuzumab Ozogamicin (CD33)

  10.7 Inotuzumab Ozogamicin (CD22)

  10.8 Ibritumomab Tiuxetan (CD20)

  10.9 Blinatumomab (CD19, CD3)

  10.10 Tisagenlecleucel (CD19)

11. Marketed Cancer CD Antigen Inhibitors Clinical and Patent Insight

  11.1 Rituximab (MabThera and Rituxan)

  11.2 Obinutuzumab (Gazyva and Gazyvaro)

  11.3 Ibritumomab Tiuxetan (Zevalin and Zevamab)

  11.4 Rituximab Biosimilar (AcellBia and USMAL)

  11.5 Rituximab Biosimilar (Reditux and Tidecron)

  11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima and Tuxella)

  11.7 Rituximab Biosimilar (Novex)

  11.8 Rituximab Biosimilar (RituxiRel, Toritz and Toritz RA)

  11.9 Rituximab Biosimilar (Maball)

  11.10 Rituximab Biosimilar (Kikuzubam)

  11.11 Rituximab Biosimilar (Mabtas)

  11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat and Remniq)

  11.13 Avelumab (BAVENCIO)

  11.14 Pembrolizumab (Keytruda)

  11.15 Atezolizumab (TECENTRIQ)

  11.16 Durvalumab (Imfinzi)

  11.17 Rituximab Biosimilar (Zytux)

12. Global CD Antigen Cancer Therapy Market Dynamics

  12.1 Market Growth Drivers

    12.1.1 Large Patient Base

    12.1.2 Unmet Medical Need

    12.1.3 Better Safety Profile

    12.1.4 Accelerated Research and Development: Newly Identified CD Antigens in Cancer

    12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market

    12.1.6 Strong Clinical Pipeline

  12.2 CD Antigen Market Challenges

    12.2.1 High Prices of CD Antigen Based Cancer Therapeutics

    12.2.2 Difficulties in Differentiating CD Target on Cancer Cells

    12.2.3 High Production Cost Due to Complex Structure

13. Global CD Antigens Cancer Therapy Market Future Forecast

14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  14.1 Research

  14.2 Preclinical

  14.3 Phase-I

15. Cancer CD 3 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  15.1 Preclinical

  15.2 Phase-I

  15.3 Phase-II

16. Cancer CD 4 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

 16.1 Phase-I

17. Cancer CD 7 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  17.1 Preclinical

18. Cancer CD 19 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  18.1 Phase-I

  18.2 Phase-I/II

  18.3 Phase-II

  18.4 Phase-III

19. Cancer CD 20 Antigen Inhibiors Clinical Pipeline by Company, Indication and Phase

  19.1 Unknown

  19.2 Research

  19.3 Preclinical

  19.4 Clinical

  19.5 Phase-I

  19.6 Phase-I/II

  19.7 Phase-II

  19.8 Phase-III

  19.9 Registered

20. Cancer CD 22 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  20.1 Preclinical

  20.2 Phase-III

  20.3 Registered

21. Cancer CD 26 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  21.1 Preclinical

  21.2 Phase-I/II

22. Cancer CD 27 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  22.1 Research

  22.2 Preclinical

  22.3 Phase-II

23. Cancer CD 30 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  23.1 Phase-I

24. Cancer CD 33 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  24.1 Phase-I

  24.2 Phase-I/II

25. Cancer CD 38 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  25.1 Research

  25.2 Preclinical

  25.3 Phase-I/II

  25.4 Phase-III

26. Cancer CD 44 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  26.1 Preclinical

  26.2 Phase-I

27. Cancer CD 45 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  27.1 Phase-III

28. Cancer CD 46 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  28.1 Research

29. Cancer CD 47 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  29.1 Research

  29.2 Preclinical

  29.3 Phase-I

  29.4 Phase-I/II

 

30. Cancer CD 52 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  30.1 Research

  30.2 Preclinical

31. Cancer CD 55 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  31.1 Preclinical

  31.2 Phase-II

32. Cancer CD 56 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  32.1 Phase-II

33. Cancer CD 66 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  33.1 Phase-I

34. Cancer CD 70 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  34.1 Phase-II

35. Cancer CD 71 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  35.1 Preclinical

36. Cancer CD 98 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  36.1 Phase-I

37. Cancer CD 200 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  37.1 Preclinical

  37.2 Clinical

  37.3 Phase-II

38. Cancer CD 223 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  38.1 Preclinical

  38.2 Phase-I

  38.3 Phase-I/II

  38.4 Phase-II

39. Cancer CD 248 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  39.1 Preclinical

  39.2 Phase-II

40. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  40.1 Research

  40.2 Preclinical

  40.3 Clinical

  40.4 Phase-I

  40.5 Phase-I/II

41. Cancer CD 319 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  41.1 Phase-I

42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

  42.1 Preclinical

  42.2 Phase-I

  42.3 Phase-I/II

43. Competitive Landscape

  43.1 AryoGen Biopharma

  43.2 Biocad

  43.3 Biogen Idec

  43.4 Celltrion

  43.5 Genentech

  43.6 Genmab

  43.7 GLYCART Biotechnology

  43.8 Hetero Drugs

  43.9 mAbxience

  43.10 MedImmune

  43.11 Merck

  43.12 Sandoz

  43.13 UCB

 

Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy

Figure 2 1: CD Antigens as Markers on Normal Leukocytes

Figure 2 2: Significance of CD Antigen in Cancer Cell and its Inhibition by Therapeutic Antibody

Figure 4-1: Types of CD Antigen Based Cancer Therapeutics

Figure 4-2: Structure of Monoclonal Antibody

Figure 4-3: Types of Therapeutic Monoclonal Antibodies

Figure 4-4: Architecture of Antibody Drug Conjugates

Figure 4-5: Bispecific Antibody Structure

Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies

Figure 5-2: Structure of Radio Immunoconjugate

Figure 5-3: Structure of Bispecific T-Cell Engager Antibody

Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody

Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab

Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin

Figure 9-1: Global – Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017

Figure 9-2: Global – CD20 Cancer Therapeutic Segmentation by Region (%), 2017

Figure 9-3: Global – Rituximab Sales (US$ Billion), 2013-2016

Figure 9-4: Global – Ofatumumab Sales (US$ Million), 2013-2016

Figure 9-5: Global – Obinutuzumab Sales (US$ Million), 2015 and 2016

Figure 9-6: Global – Ibritumomab Tiuxetan Sales (US$ Million), 2013-2016

Figure 9-7: Global – Daratumumab Sales (US$ Million), 2015-2017*

Figure 9-8: Global – Daratumumab Half Yearly Sales (US$ Million), 2016 and 2017

Figure 9-9: Global – Brentuximab Vedotin Sales (US$ Million), 2014-2017

Figure 9-10: Global – Blinatumomab Sales (US$ Million), 2015-2017*

Figure 9-11: Global – Blinatumomab Sales (US$ Million), 2015-2017

Figure 9-12: Global – Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-13: Global – Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-14: Global – Cancer CD 3 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-15: Global – Cancer CD 3 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-16: Global – Cancer CD 19 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-17: Global – Cancer CD 19 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-18: Global – Cancer CD 20 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-19: Global – Cancer CD 20 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-20: Global – Cancer CD 22 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-21: Global – Cancer CD 22 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-22: Global – Cancer CD 26 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-23: Global – Cancer CD 26 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-24: Global – Cancer CD 27 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-25: Global – Cancer CD 27 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-26: Global – Cancer CD 33 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-27: Global – Cancer CD 33 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-28: Global – Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-29: Global – Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-30: Global – Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-31: Global – Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-32: Global – Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-33: Global – Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-34: Global – Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-35: Global – Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-36: Global – Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-37: Global – Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-38: Global – Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-39: Global – Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-40: Global – Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-41: Global – Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-42: Global – Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-43: Global – Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-44: Global – Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-45: Global – Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-46: Global – Cancer CD Miltiple Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-47: Global – Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017

Figure 9-48: Global – Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-49: Global – Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 10-1: US – Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2017

Figure 10-2: US – Rituximab Vial Price by Quantity (US$), 2017

Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US$), 2017

Figure 10-4: US – Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US$/Unit), 2017

Figure 10-5: US – Ofatumumab Vial Price by Quantity (US$), 2017

Figure 10-6: Ofatumumab – Treatment Dosage Analysis (mg)

Figure 10-7: Ofatumumab – Price Analysis by Dosage (US$)

Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)

Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)

Figure 10-10: US – Obinituzumab Solution Price (US$), 2017

Figure 10-11: Obinutuzumab – Therapy First Cycle Average Cost (US$), 2017

Figure 10-12: Obinutuzumab Average Treatment Cost (US$), 2017

Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)

Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)

Figure 10-15: US – Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US$/Unit), 2017

Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US$), 2017

Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US$), 2017

Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US$), 2017

Figure 10-19: US – Brentuximab Vedotin Price Analysis, (US$), 2017

Figure 10-20: US – Brentuximab Vedotin Treatment Expenditure (US$), 2014

Figure 10-21: US – Brentuximab Vedotin Treatment Cost (US$), 2017

Figure 10-22: Global – Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US$), 2010 and 2017

Figure 10-23: US – Ibritumomab Tiuxetan Product and Dose Price Analysis (US$), 2017

Figure 10-24: US – Blinatumomab Dosage Average Price Analysis (US$), 2017

Figure 10-25: US – Blinatumomab Treatment First Cycle Average Cost (US$), 2017

Figure 10-26: US – Blinatumomab Treatment Subsequent Cycle Average Cost (US$), 2017

Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors

Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate

Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges

 

 

 

Table 10-1: Rituximab Dosage Indications for Treatment of Different Cancer Conditions

Sign up and submit a press release

Sponsored
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

Fluidx Unveils New Embolic for Neurovascular Use

Fluidx Unveils New Embolic for Neurovascular Use

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

PT Genie Unveils New Brand Identity Reflecting Company’s Transformation and Focus on the Global Future of AI and Machine Learning in Digital Healthcare

interviews & reviews
Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
Posting....
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email